Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 296, Issue 2, 2009, Pages

  Zhu, Bing ^a   Zhang, Li ^a   Alexeyev, Mikhail ^b   Alvarez, Diego F ^b   Strada, Samuel J ^a   Stevens, Troy ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Migration; Nitric oxide; Proliferation; Sildenafil; Vasculogenesis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; MATRIGEL; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; LUNG ARTERY; LUNG ENDOTHELIUM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LAMININ; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; PROTEOGLYCANS; PULMONARY ARTERY; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 59449085665     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.90474.2008     Document Type: Article

References (40)

1. Al-Ani B, Hewett PW, Ahmed S, Cudmore M, Fujisawa T, Ahmad S, Ahmed A. The release of nitric oxide from S-nitrosothiols promotes angiogenesis. PLoS ONE 1: e25, 2006.
2. Alvarez DF, Huang L, King JA, Elzarrad MK, Yoder MC, Stevens T. Lung microvascular endothelium is enriched with progenitor cells that exhibit vasculogenic capacity. Am J Physiol Lung Cell Mol Physiol 294: L419-L430, 2008.
3. Benedict N, Seybert A, Mathier MA. Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 29: 2134-2153, 2007.
4. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 159: 993-1008, 2001.
5. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
6. Chen H, Levine YC, Golan DE, Michel T, Lin AJ. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phos-phoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem 283: 4439-4447, 2008.
7. Cioffi DL, Moore TM, Schaack J, Creighton JR, Cooper DM, Stevens T. Dominant regulation of interendothelial cell gap formation by calcium-inhibited type 6 adenylyl cyclase. J Cell Biol 157: 1267-1278, 2002.
8. Clark J, Alvarez DF, Alexeyev M, King JA, Huang L, Yoder MC, Stevens T. Regulatory role for nucleosome assembly protein-1 in the proliferative and vasculogenic phenotype of pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol 294: L431-L439, 2008.
9. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 438: 937-945, 2005.
10. Creighton J, Zhu B, Alexeyev M, Stevens T. Spectrin-anchored phos-phodiesterase 4D4 restricts cAMP from disrupting microtubules and inducing endothelial cell gap formation. J Cell Sci 121: 110-119, 2008.
11. Croom KF, Curran MP. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68: 383-397, 2008.
12. Folkman J, Shing Y. Angiogenesis. J Biol Chem 267: 10931-10934, 1992.
13. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148-2157, 2005.
14. Hristov M, Zernecke A, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, Weber C. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res 100: 590-597, 2007.
15. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436, 2004.
16. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101: 1084-1095, 2007.
17. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. Bio Drugs 22: 37-44, 2008.
18. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635, 2005.
19. King J, Hamil T, Creighton J, Wu S, Bhat P, McDonald F, Stevens T. Structural and functional characteristics of lung macro- and microvascular endothelial cell phenotypes. Microvasc Res 67: 139 -151, 2004.
20. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperox-ia-induced lung injury. Am J Respir Crit Care Med 172: 750-756, 2005.
21. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, Vasanji A, Drazba J, Anand-Apte B, Erzurum SC. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548-L554, 2007.
22. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A, Kharitonenkov A. Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 210: 1-6, 2007.
23. Murray F, MacLean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 137: 1187-1194, 2002.
24. Naito Y, Katada K, Takagi T, Tsuboi H, Kuroda M, Handa O, Kokura S, Yoshida N, Ichikawa H, Yoshikawa T. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. World J Gastroenterol 12: 2024-2030, 2006.
25. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angio-genesis. Mol Pharmacol 67: 263-272, 2005.
26. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206, 2000.
27. Pyriochou A, Beis D, Koika V, Potytarchou C, Papadimitriou E, Zhou Z, Papapetropoulos A. Soluble guanylyl cyclase activation promotes angiogenesis. J Pharmacol Exp Ther 319: 663-671, 2006.
28. Reitman ML. FGF21: a missing link in the biology of fasting. Cell Metab 5: 405-407, 2007.
29. Solodushko V, Fouty B. Proproliferative phenotype of pulmonary micro-vascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 292: L671-L677, 2007.
30. Stevens T, Creighton J, Thompson WJ. Control of cAMP in lung endothelial cell phenotypes. Implications for control of barrier function. Am J Physiol Lung Cell Mol Physiol 277: L119-L126, 1999.
31. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF. The pathobiology of pulmonary hypertension. Endothelium Clin Chest Med 22: 405-418, 2001.
32. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106: 913-919, 2002.
33. Wharton J, Strange JW, Moller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodies-terase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172: 105-113, 2005.
34. Yamahara K, Itoh H, Chun TH, Ogawa Y, Yamashita J, Sawada N, Fukunaga Y, Sone M, Yurugi-Kobayashi T, Miyashita K, Tsujimoto H, Kook H, Feil R, Garbers DL, Hofmann F, Nakao K. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-depen-dent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci USA 100: 3404-3409, 2003.
35. Zhang L, Zhang Z, Zhang RL, Cui Y, LaPointe MC, Silver B, Chopp M. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke. Brain Res 1118: 192-198, 2006.
36. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z, Chopp M. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res 92: 308-313, 2003.
37. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol 50: 139-148, 2000.
38. Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodies-terase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 7: 437-454, 2007.
39. Zhu B, Strada S, Stevens T. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289: L196-L206, 2005.
40. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94: 336-350, 2005.